Cure HHT Awards $180,000 for Global Research

Share Article

Cure HHT, the only US nonprofit organization that supports HHT patients and their families, is happy to announce the winners of the 2015 Young Scholar Research Grants. Each of the projects, all of which were submitted by young PhD researchers from across the world, endeavors to advance HHT treatment while bringing science closer to a cure for hereditary hemorrhagic telangiectasia (HHT).

It’s this level of dedication that will lead to a cure.

Cure HHT, the only US nonprofit organization that supports HHT patients and their families, is happy to announce the winners of the 2015 Young Scholar Research Grants. Each of the projects, all of which were submitted by young PhD researchers from across the world, endeavors to advance HHT treatment while bringing science closer to a cure for hereditary hemorrhagic telangiectasia (HHT).

“We are amazed at the passion and interest young researchers show for the Cure HHT cause,” said Executive Director Marianne Clancy. “This is the first year we have been able to fund six projects, and we expect great things to come from all of them. It’s this level of dedication that will lead to a cure.”

Chadwick Davis, PhD with Recursion Pharmaceuticals - Dr. Davis is utilizing high-content cellular imaging and advanced software to evaluate the reaction of mutated HHT genes in response to 2,727 known drugs and bioactive compounds.

Roxana Ola, PhD with Yale University School of Medicine – Dr. Ola is studying arteriovenous malformations in mice to target signaling components that will reverse the formation process. Results could influence drug design of ALK1-based arteriovenous shunt inhibition.

Hongyu Tian, PhD with Duke University - Dr. Tian is determining endoglin's role in vascular muscle cells during developmental angiogenesis, the process of new blood vessels forming from old ones.

Simon Tual-Chalot, PhD with Newcastle University - Dr. Tual-Chalot is studying the relation of endoglin to heart function to investigate high output heart failure in HHT.

Whitney Wooderchak-Donahue, PhD with University of Utah and ARUP Laboratories - Dr. Wooderchak-Donahue is identifying genetic modifiers of the HHT phenotype in family members who have an ENG or ACVRL1 mutation and explaining the genetic basis of vascular malformations in those who do not have a known ENG, ACVRL1 or SMAiD4 mutation.

Wan Zhu, PhD with University of California, San Francisco - Dr. Zhu will investigate an innovative and noninvasive strategy for treating brain arteriovenous malformations, with a focus on limited or eliminating side effects.

About Cure HHT:
Cure HHT is the ONLY 501(c)(3) non-profit organization in the world committed to bringing together international thought leaders, working collaboratively to find a cure for HHT. Cure HHT is also the sole provider of HHT education programs and resources for patients and physicians worldwide. For more information, visit http://www.curehht.org.

Contacts:
Nicole Schaefer
Cure HHT
nicole.schaefer(at)curehht(dot)org
410-357-9932

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lauren Linhard
Cure HHT
+1 410-357-9932
Email >

Lauren Linhard, Communications Associate
Cure HHT
410-357-9932
Email >
Visit website